NCT01034462 - Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder | Biotech Hunter

Enrollment

442

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Major Depressive Disorder

Interventions

DRUG

Levomilnacipran ER

Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks

DRUG

Placebo

Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.

Trial Locations (23)

11214

Forest Investigative Site 051, Brooklyn

18104

Forest Investigative Site 054, Allentown

23452

Forest Investigative Site 068, Virginia Beach

30080

Forest Investigative Site 066, Smyrna

30328

Forest Investigative Site 070, Atlanta

32607

Forest Investigative Site 064, Gainesville

32789

Forest Investigative Site 059, Winter Park

32806

Forest Investigative Site 061, Orlando

33431

Forest Investigative Site 057, Boca Raton

33432

Forest Investigative Site 060, Boca Raton

34471

Forest Investigative Site 053, Ocala

36305

Forest Investigative Site 055, Dothan

46260

Forest Investigative Site 063, Indianapolis

60523

Forest Investigative Site 050, Oak Brook

60634

Forest Investigative Site 072, Chicago

66206

Forest Investigative Site 071, Prairie Village

71104

Forest Investigative Site 052, Shreveport

73112

Forest Investigative Site 056, Oklahoma City

Forest Investigative Site 067, Oklahoma City

78229

Forest Investigative Site 062, San Antonio

80130

Forest Investigative Site 065, Highlands Ranch

97301

Forest Investigative Site 058, Salem

99204

Forest Investigative Site 069, Spokane